Skip to main content

Table 1 Demographic characteristics of the patients, ANA status at baseline and characteristics of the infusion reactions

From: Predictors of infusion reactions during infliximab treatment in patients with arthritis

Characteristic

RA (n = 213)

SpAs (n = 76)

Age at inclusion (years)

55.9 ± 14.0

45.0 ± 13.1

Age at disease onset (years)

43.2 ± 15.2

31.9 ± 13.1

Disease duration at start (years)

12.6 ± 10.0

13.1 ± 11.0

Treatment duration at infusion reaction (months)

11.5 ± 9.6

4.3 ± 4.3

Number of previous DMARDs

3.3 ± 1.7

1.9 ± 1.1

Female

156 (73.2%)

40 (52.6%)

ANA positivity (yes)

56/201 (27.9%)

18/72 (25.0%)

Infusion reaction (yes)

45 (21.1%)

10 (13.2%)

Infusion reaction leading to withdrawal of treatment

33/45 (73.3 %)

9/10 (90%)

  1. Values are expressed as mean ± standard deviation or as number (%). ANA, antinuclear antibody; DMARD, disease-modifying antirheumatic drug.